Revenue (Tables)

12 Months Ended

Dec. 31, 2020

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue

The following table summarizes our revenue recognized in our consolidated statements of operations:

	2020		2019		2018
Net product revenue	$	22,694.8	$	20,377.3	$	19,866.4
Collaboration and other revenue(1)	1,845.0		1,942.2		1,626.9
Revenue	$	24,539.8	$	22,319.5	$	21,493.3

(1) Collaboration and other revenue associated with prior period transfers of intellectual property was $135.6 million, $301.5 million, and $303.2 million during the years ended December 31, 2020, 2019, and 2018, respectively.

The following table summarizes revenue by product:

	U.S.						Outside U.S.
	2020		2019		2018		2020		2019		2018
Revenue—to unaffiliated customers:
Diabetes:
Trulicity®	$	3,835.9	$	3,155.2	$	2,515.8	$	1,232.2	$	972.7	$	683.3
Humalog® (1)	1,485.6		1,669.7		1,787.8		1,140.3		1,151.0		1,208.7
Humulin®	866.4		879.7		910.2		393.2		410.4		421.2
Jardiance (2)	620.8		565.9		400.2		533.0		378.3		258.1
Basaglar®	842.3		876.2		622.8		282.1		236.3		178.5
Trajenta (3)	95.6		224.8		224.2		263.0		365.8		350.5
Other Diabetes	162.5		158.0		146.0		81.5		88.1		112.2
Total Diabetes	7,909.1		7,529.5		6,607.0		3,925.3		3,602.6		3,212.5
Oncology:
Alimta®	1,265.3		1,219.5		1,131.0		1,064.7		896.4		1,001.9
Cyramza®	381.9		335.3		291.5		650.8		589.9		529.9
Verzenio®	618.2		454.8		248.5		294.4		124.9		6.6
Erbitux®	480.1		487.9		531.6		56.3		55.4		103.8
Other Oncology	46.6		111.0		200.6		461.0		339.3		215.1
Total Oncology	2,792.1		2,608.5		2,403.2		2,527.2		2,005.9		1,857.3
Immunology:
Taltz®	1,288.5		1,016.8		738.7		500.0		349.6		198.7
Olumiant®	63.8		42.2		6.7		575.0		384.7		195.9
Other Immunology	20.0		—		—		14.6		—		—
Total Immunology	1,372.3		1,059.0		745.4		1,089.6		734.3		394.6
Neuroscience:
Cymbalta®	42.1		49.6		54.3		725.6		675.8		653.7
Zyprexa®	46.1		41.0		36.2		360.5		377.6		435.1
Emgality®	325.9		154.9		4.9		37.0		7.7		—
Other Neuroscience	73.2		111.0		182.0		220.9		305.3		454.5
Total Neuroscience	487.3		356.5		277.4		1,344.0		1,366.4		1,543.3
Other:
Forteo®	510.3		645.5		757.9		536.0		759.1		817.7
Bamlanivimab (4)	850.0		—		—		21.2		—		—
Cialis®	61.8		231.7		1,129.2		545.4		658.8		722.7
Other	246.4		291.9		471.8		321.8		469.7		553.3
Total Other	1,668.4		1,169.1		2,358.8		1,424.4		1,887.7		2,093.7
Revenue	$	14,229.3	$	12,722.6	$	12,391.9	$	10,310.5	$	9,596.8	$	9,101.4

Numbers may not add due to rounding.

(1) Humalog revenue includes insulin lispro.

(2) Jardiance revenue includes Glyxambi® and Synjardy®, and Trijardy® XR.

(3) Trajenta revenue includes Jentadueto®.

(4) Bamlanivimab sales are pursuant to EUA.

The following table summarizes revenue by geographical area:

	2020		2019		2018
Revenue—to unaffiliated customers(1):
U.S.	$	14,229.3	$	12,722.6	$	12,391.9
Europe	4,187.7		3,765.0		3,663.1
Japan	2,583.1		2,547.6		2,407.4
China	1,116.9		939.4		750.8
Other foreign countries	2,422.7		2,344.9		2,280.1
Revenue	$	24,539.8	$	22,319.5	$	21,493.3

Numbers may not add due to rounding.

(1) Revenue is attributed to the countries based on the location of the customer.

Schedule of Amounts Recorded for Contract Liabilities

The following table summarizes contract liability balances:

	2020		2019
Contract liabilities	$	276.8	$	264.6